NCT03188705View on ClinicalTrials.gov

CES1 Carriers in the PAPI Study

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

January 17, 2020

Study Completion Date

January 17, 2020

Conditions
Heart DiseasesCoronary DiseaseCoronary Artery DiseaseCardiovascular DiseasesMyocardial IschemiaArtery OcclusionAspirin SensitivityClopidogrel, Poor Metabolism ofPlatelet DysfunctionPlatelet Thrombus
Interventions
DRUG

Clopidogrel

Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

DRUG

Aspirin

Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.

Trial Locations (1)

17602

Amish Research Clinic, Lancaster

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT03188705 - CES1 Carriers in the PAPI Study | Biotech Hunter | Biotech Hunter